Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Shares Traded Last Trade
  -6.00 -0.71% 841.00 433,984 16:35:15
Bid Price Offer Price High Price Low Price Open Price
844.00 847.00 855.00 830.00 849.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 64.06 -20.89 -22.10 691
Last Trade Time Trade Type Trade Size Trade Price Currency
17:59:45 O 44,230 840.916 GBX

Oxford Biomedica (OXB) Latest News

More Oxford Biomedica News
Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica Forums and Chat

Date Time Title Posts
19/9/202020:21Feck off the_doctor9,759
17/9/202021:25Oxford Biomedica1,477
17/9/202001:00Truth Vs. Deception23
06/9/202013:57Oxford Biomedica - closer to a cure for Parkinson's Disease ?7
16/7/202010:41Oxford Biomedica Bulls Only Thread31,094

Add a New Thread

Oxford Biomedica (OXB) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

Oxford Biomedica Daily Update: Oxford Biomedica Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 847p.
Oxford Biomedica Plc has a 4 week average price of 750p and a 12 week average price of 701p.
The 1 year high share price is 899p while the 1 year low share price is currently 366p.
There are currently 82,130,020 shares in issue and the average daily traded volume is 108,819 shares. The market capitalisation of Oxford Biomedica Plc is £690,713,468.20.
gareth jones: Apologies, to Mr President, Sir and one and all for the poor play on words (twice). OXB never ceases to surprise you. With all the COVID news surrounding the company, the cash raised Overnight during the pandemic, the charge towards profitability, spare manufacturing suites ready to go and MRHA approved in OXBOX, the training of staff for the new Vaccine Institute in Oxford for HMG, the anticipation of three more deals before Christmas and an in house product being out Sourced, the Biotech sector being described the “hot” sector at the moment and US Biotech company valuations surging on NASDAQ along with increased M&A activity...the OXB share price remains pretty much unmoved. At least it gives more time to buy more Shares and tuck in the ISA before the lid blows off the share price (hopefully). I think many of us LTH’s think we are in a better place than we have ever been in our short listed history. St Ives in the morning, good luck next week all LTH’s.
gareth jones: It’s supposed to be the Glorious 12th today. The weather is certainly supporting this fact. Please can we have no more “47% undervalued” comments please, as you are aware OXB share price is normally inversely proportional to positive comment. Abandon hope all ye that consider investing. Only joking, the Summer doldrums will soon be over hopefully before the trade winds pick up and we enter the “roaring forties”.
marcusl2: Good find Kingzog There are stocks out there that I class as ‘coronavirus stocks’. Oxford Biomedica (LSE:OXB) is one such stock and I believe it could be a good growth share over time. Oxford Biomedica is a gene and cell therapy company and is an offshoot from Oxford University. It specialises in gene-based medicine and is currently listed on the FTSE 250. Projects, partnerships & performance OXB owns many of its own platforms related to gene-based therapies. One of its platforms, LentiVector, is the first of its kind and recognised worldwide as a leading platform. It usually partners with larger pharmaceutical companies and currently has partnerships with recognised pharma giants such as Novartis and AstraZeneca. The partnership with AstraZeneca is what makes me class OXB as a coronavirus stock and an attractive proposition. OXB’s share price has increased over 80% in the last five years, which is impressive in my opinion. When the market crashed, its share price dropped from nearly 700p per share, down to 400p. But it has recovered nicely to over 800p per share as I write this. Just last week, AstraZeneca released its interim results in which it highlighted its work around coronavirus with OXB. Recent trials have shown that the drug being tested increased antibodies four-fold. These results were maintained after two months+ had passed. Additionally, neutralising activity was seen in 91% of patients tested and 100% of those who had a second dose. I consider such results a step forward in the fight against coronavirus and a positive achievement for OXB. Last year, Denmark’s Novo Holdings, acquired just over 10% of the firm to support its gene therapy products and this allowed Oxford Biomedica to clear its debts in full. In full-year results to December 31 2019, OXB incurred an operating EBITDA loss of £5.2m compared to a £13.4m profit the year before. Revenue decreased by 4% to £64.1 million over that period. But the loss does not concern me. OXB has invested millions into better facilities and infrastructure to enhance its operations, which includes the coronavirus-focused work. Coronavirus stock opportunity What I really like about OXB as a coronavirus stock is its record to date and strategic partnerships. The fact that a pharmaceutical giant such as AstraZeneca has partnered with it around the coronavirus gives me confidence. And the company seems confident too. Last year it built a new $50m facility for which it borrowed the money and repaid promptly. Just last month it raised £40m in funds to continue its work. Yes, it is loss-making. But it is also debt-free, raising funds and partnering with some of the biggest pharmaceutical companies out there. Hence I feel there is less risk involved when it comes to OXB than some others among its peers. As coronavirus stocks go, this is one I would seriously consider. It has shown that it can deliver results scientifically, and has turned a profit too before its most recent loss. Of course there are plenty of coronavirus stocks out there. But I feel at such an attractive price, OXB could be a great growth opportunity. The post I believe this coronavirus stock could be a great growth opportunity appeared first on The Motley Fool UK. Jabran Khan July 2020
harry s truman: I hope so Pram, but you are of course correct. Thinking about it they are offloading up to 3 million shares into a market which is not operating under normal conditions, with at least a quarter of their holding already gone. The result on the OXB share price has been negligible, whereas if the demand hadn't been there we would have dropped pounds in a very short period of time.
for fx sake: I'm beginning to think that the good ship Pending Deal has well and truly sailed. I suspect the delay in results (and they are now late compared to previous years) is more to do with damage limitation. Nobody would want to release lacklustre results in the current climate while others might want to release good results just to bolster and protect the share price. The board have remained tight-lipped for too long now. In the absence of any communication, the stark facts are that: - The OXB share price continues to plunge. - Axovant look even bleaker. - State health services are being crippled by coronavirus. In the aftermath of all this, when the bean counters are counting the cost, are they really going to have an appetite for funding 400k one-off treatments or are they going to wither back to less effective cheaper options.
harry s truman: FFS, As you say, the OXB share price is often a mystery. We all know that JD needs to announce deals. Unfortunately those announcements haven't met forecasts yet (but we live in hope). The coronavirus comparison to Italy is a big if (as you note). Perhaps you saw the same lady professor on the TV last night, but she was basically saying that we find out in the next week or two whether the NHS's infection control people have managed to flatten the curve or not. As I understand it, that is the big hope and the point of ruthlessly tracking down contacts of those tested positive so far. We can only trust in people who spend their lives planning for things like this and they seem to be doing a good job to me.
singsling: Fair enough. Vulpes is a very passionate shareholder and a true believer if there ever was one. SD tends to suffer a bout of Tourette's if OXB share price is mentioned in conversation. No chance of a cheap exit from them or any of the top 10.
fp optimist: IMHO - noodling around with share price around 650 on the basis of no news sounds about right. 2019 was a failure in relation to OXb' management and their own criteria - 1) Moving from profit to loss (announced in the summer) 2) Next to nothing in the way of new licences, (where JD was very bullish) 3) On news of production capacity (OxBox completion?). The "yes buts" are 1) Thank goodness for Axovant moving forward and 2) The encouraging figures from Novartis sales volume build up late in the year (thanks Slingsling). Marcus has always been reassuring about progress in our general area, but I look forward to that being translated in interest in OXB share price.
beanol: Yes Harry certainly I feel the absence of the promised news is unfortunate. It wasn't just at the AGM the guidance was reiterated publicly and also in a private letter which I replayed here. All that said my sense is that the absence of news and the absence of any news or further guidance is not serious and that these fiendishly complex deals (JD said more than - note a recent comment from Pram) are just taking longer than reasonably expected. I don't expect as much (now) from Axovant as I was expecting. The news you reported of a massive massive capital raise seems to have sucked the life out of the Axovant share price recently but hopefully I am wildly wrong about this. The gradual recovery of the oxb share price on low volume is very welcome and will hopefully be a good springboard for a much higher share price when one or more new deals are announced. And then a takeover at 20 in the autumn!
biopop: iirc the oxb share price usually goes up in advance of results and then falls afterwards so not sure what happening at the moment. Would be good to know what/if anything they plan to do with the eye products and will be interesting if they say anything about Nasdaq and if we are close to new deals!
Oxford Biomedica share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200920 01:33:34